]>
IRCT20220117053743N3 IRCT 2026-10-08 Esfahan University of Medical Sciences Efficacy and Safety of 2.5 mg versus 5 mg Oral Minoxidil for Androgenetic Alopecia: A Comparative Study Efficacy and Safety of 2.5 mg versus 5 mg Oral Minoxidil for Androgenetic Alopecia: A Comparative Study 2026-11-20 anticipated 58 Pending https://irct.ir/trial/93310 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This is a randomized, double-blind, parallel-group comparative clinical trial conducted in 58 male patients aged 19–45 years with androgenetic alopecia (Hamilton–Norwood grade 1–4). Participants are allocated to receive oral minoxidil 2.5 mg or 5 mg once daily for 6 months. Clinical assessments, blood pressure, heart rate, and lower-extremity edema are monitored monthly. Hair density and hair shaft diameter are assessed at baseline and after 6 months using standardized scalp photography and dermoscopy, Randomization description: Participants will be randomly allocated to two separate groups according to a randomization schedule, Blinding description: The patient and the outcome assessor are blinded to the dose allocation. 3 Androgenetic Alopecia. Intervention group: 5mg daily minoxidil. No - There is not a plan to make this available Justification or reason for not sharing IPD is Individual participant data will not be shared publicly due to privacy and confidentiality considerations. Only aggregated and anonymized study results will be reported in the final publication.
public aida Farmani
Isfahan university of medical
Isfahan Iran (Islamic Republic of) 8158799346 +98 913 409 0453 aida.farmani.med@gmail.com Esfahan University of Medical Sciences scientific Aida Farmani
Isfahan university of medical
Isfahan Iran (Islamic Republic of) 8158799346 +98 913 409 0453 aida.farmani.med@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Male patients aged 19–45 years with clinically diagnosed androgenetic alopecia, classified as Hamilton–Norwood grade 1–4, who provide informed consent to participate in the study. 19 years 45 years Male patients with a history of cardiovascular disease, hypotension, renal disease, severe drug hypersensitivity (TEN, Stevens–Johnson syndrome, or DRESS syndrome), or arrhythmia (non-sinus rhythm on electrocardiography) will be excluded from the study L64 Androgenic alopecia Treatment - Drugs Intervention group: 5mg daily minoxidil Improvement of hair density. Timepoint: 6 month. Method of measurement: Software. Esfahan University of Medical Sciences Approved 2026-05-22 Esfahan University of Medical Sciences Hezarjerib Esfahan Isfehan Iran (Islamic Republic of)